RT Journal Article
SR Electronic
T1 SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20166876
DO 10.1101/2020.08.02.20166876
A1 Ebinger, Joseph E.
A1 Botwin, Gregory J.
A1 Albert, Christine M.
A1 Alotaibi, Mona
A1 Arditi, Moshe
A1 Berg, Anders H.
A1 Binek, Aleksandra
A1 Botting, Patrick
A1 Fert-Bober, Justyna
A1 Figueiredo, Jane C.
A1 Grein, Jonathan D.
A1 Hasan, Wohaib
A1 Henglin, Mir
A1 Hussain, Shehnaz K.
A1 Jain, Mohit
A1 Joung, Sandy
A1 Karin, Michael
A1 Kim, Elizabeth H.
A1 Li, Dalin
A1 Liu, Yunxian
A1 Luong, Eric
A1 McGovern, Dermot P.B.
A1 Merchant, Akil
A1 Merin, Noah
A1 Miles, Peggy B.
A1 Nguyen, Trevor-Trung
A1 Raedschelders, Koen
A1 Rashid, Mohamad A.
A1 Riera, Celine E.
A1 Riggs, Richard V.
A1 Sharma, Sonia
A1 Sobhani, Kimia
A1 Sternbach, Sarah
A1 Sun, Nancy
A1 Tourtellotte, Warren G.
A1 Eyk, Jennifer E. Van
A1 Braun, Jonathan G.
A1 Cheng, Susan
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166876.abstract
AB Of individuals with SARS-CoV-2 IgG antibody testing performed, those who contemporaneously experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more likely to test negative. These findings suggest that antibodies likely wane over a period of months, particularly in relation to the timing of symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Cedars Sinai Medical Center and the Erika J. Glazer Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols were approved by the Cedars Sinai institutional review board and all participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from Cedars-Sinai Medical Center, upon reasonable request. The data are not publicly available due to the contents including information that could compromise research participant privacy/consent.